ArticleEuropean journal of haematology2025
European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.
Article in European journal of haematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Transition from inpatient to outpatient step-up dosing of bispecific antibodies in multiple myeloma: real-world insights.Blood advances · 2026Article
- Article
- European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions.European journal of haematology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
objectivesTeclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission). An expert consensus survey and meeting were conducted among European specialists in multiple myeloma treatment to evaluate current and future outpatient administration with teclistamab and talquetamab in clinical practice.
methodsAll experts completed a 17-question survey, participated in an individual follow-up call, and attended an online consensus meeting in September 2024.
resultsThere was strong agreement that outpatient treatment with teclistamab and talquetamab is feasible, with implementation already seen in some centers. Factors identified as potential criteria to define patient eligibility include cognitive status, caregiver presence, and distance from the hospital. While outpatient administration is not yet widely adopted due to limited experience with bispecific antibodies, the expert panel expects up to 50% of patients receiving teclistamab and talquetamab could be treated in an outpatient setting within 3 years.
conclusionsSharing best practices, robust protocol development, and evidence from clinical trials and real-world experience will support the implementation of outpatient treatment with bispecific antibodies, which could relieve hospital resources and improve patients' treatment experience.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.